Business & Profession Business and Innovation, Professional Development

Business in Brief

Allergan and Editas join forces, Carl Zeiss win a patent infringement case, and more…

Roisin McGuigan | 04/06/2017

Pharmaceutical giant Allergan has entered into an R&D agreement with new kid on the block and CRISPR specialist Editas Medicine to discover and develop therapies based on genome-editing for ocular diseases. Editas will receive $90 million upfront while Allergan will be able to license up to five candidate programs targeting eye disease. The first could be a lead candidate for Leber Congenital Amaurosis (LCA10) that is currently in the preclinical stage but predicted to enter the clinic later this year.
Bill Ackman has announced that Pershing Square Capital Management has sold all shares in Valeant, and says that he is “deeply and profoundly” sorry for his investment in Valeant, writing in a letter “Clearly, our investment in Valeant was a huge mistake. We deeply regret this mistake, which has cost all of us a tremendous amount, and which has damaged the record of success of our firm.”
Meanwhile, Valeant’s former CEO, Michael Pearson, is suing the company, claiming that it failed to pay him three million shares as part of his exit package.

Business & Profession Business and Innovation, Professional Development

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as a deputy editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.